Hikma Announces FDA Approval

Hikma Pharmaceuticals Plc
25 January 2006



                                                                25 January 2006

  Hikma Announces FDA Approval of Saudi Arabian Manufacturing Facility for the
                    Production of Oral Cephalosporin Products
                                        
Hikma Pharmaceuticals PLC (LSE: HIK), the multinational pharmaceuticals group,
today announced that the US FDA has approved its Abbreviated New Drug
Application (ANDA) filings for the oral cephalosporin, Cephalexin in 250mg and
500 mg capsule form. These products will be manufactured by Jazeera
Pharmaceutical Industries (JPI), Hikma's 47.5 per cent. owned associate company
in Riyadh, Saudi Arabia, for sale in the US market. JPI has received US FDA
approval for the manufacture of oral Cephalosporin products.

JPI is the first company in the Gulf area with FDA approved facilities and all
of Hikma's major manufacturing sites in the US, Jordan, Portugal and Saudi
Arabia are now FDA approved.

                                    - ENDS -

Enquiries:

Hikma Pharmaceuticals plc

Bassam Kanaan, Chief Financial Officer                          [phone]
Susan Ringdal, Investor Relations Director                      [phone]

Brunswick Group

Jon Coles / Wendel Verbeek / Justine McIlroy / Alex Tweed       [phone]

Notes to Editors

About Hikma
Hikma Pharmaceuticals plc (LSE: HIK) is a multinational pharmaceutical group
focused on developing, manufacturing and marketing a broad range of both branded
and non-branded generic and in-licensed pharmaceutical products. Hikma's
operations are conducted through three businesses: Generic, Branded and
Injectable Pharmaceuticals. Hikma's operations are based principally in the
United States, the Middle East and North Africa ('MENA') Region, and Europe. The
Company had net sales of $214m in 2004 and had approximately 1730 employees as
at 30 September 2005.

About JPI
Hikma's associate company in Saudi Arabia, JPI, has a 15,100 square metre
facility in Riyadh. This facility has the capacity to manufacture 500 million
tablets, 150 million capsules, 30 million bottles, 20 million suppositories, as
well as two million tubes of ointments. JPI's facility has been certified by the
Saudi Arabian Ministry of Health and the State Institute for Drug control in
Slovakia, and is FDA approved.



                      This information is provided by RNS
            The company news service from the London Stock Exchange